Showing results (281-290 of 366) with videos related to

Sort By:
Pageof 37
Bioorganic & Medicinal Chemistry|October 20, 2006
Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110alpha inhibitorsMasahiko Hayakawa, Hiroyuki Kaizawa, Ken-Ichi Kawaguchi, et al.
Assay and Drug Development Technologies|July 20, 2007
Application of meso scale technology for the measurement of phosphoproteins in human tumor xenograftsSharon M Gowan, Anthea Hardcastle, Albert E Hallsworth, et al.
Journal of Medicinal Chemistry|April 28, 2016
Exploiting Protein Conformational Change to Optimize Adenosine-Derived Inhibitors of HSP70Matthew D Cheeseman, Isaac M Westwood, Olivier Barbeau, et al.
Molecular Cell|October 17, 2008
Hsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37Cara K Vaughan, Mehdi Mollapour, Jennifer R Smith, et al.
Cancer Research|January 7, 2006
Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma modelsNada M S Al-Saffar, Helen Troy, Ana Ramírez de Molina, et al.
Molecular Cancer Therapeutics|October 18, 2005
Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activityLindsay Stimson, Martin G Rowlands, Yvette M Newbatt, et al.
Nucleic Acids Research|January 10, 2023
canSAR: update to the cancer translational research and drug discovery knowledgebasePatrizio di Micco, Albert A Antolin, Costas Mitsopoulos, et al.
Cancer Research|October 12, 2010
MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signatureNathalie Gaspar, Lynley Marshall, Lara Perryman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumorsJohann S de Bono, Rebecca Kristeleit, Anthony Tolcher, et al.
Molecular Cancer Therapeutics|June 24, 2026
Anti-Tumor Activity of Cdk2/9 Inhibitor Fadraciclib in an In Vivo Model of Temozolomide Refractory NeuroblastomaEvon Poon, Tong Liang, Qiong Gao, et al.
Pageof 37